Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.
Accid Anal Prev. 2012 Mar;45:498-506. doi: 10.1016/j.aap.2011.09.003. Epub 2011 Sep 25.
The on-the-road driving test in normal traffic is applied to examine the impact of drugs on driving performance. Although participants are accompanied by a licensed driving instructor, under Dutch law, the driver is primarily responsible for safe driving and is not permitted to continue driving when it is judged that the drug compromises safety. This review examined the prevalence and nature of stopped driving tests, and the relationship with Standard Deviation of Lateral Position (SDLP), i.e. the "weaving of the car".
A literature search was conducted to gather all publications on clinical trials that applied the on-the-road driving test, examining the effects of Central Nervous System (CNS)-drugs such as anxiolytics, antidepressants, antihistamines, analgesics, and hypnotics.
47 papers reported on 50 Dutch clinical trials in which 1059 subjects participated (903 healthy volunteers and 156 patients). A total of 7232 driving tests were performed; 5050 after drug treatment and 2042 after placebo. 3.1% of all driving tests were terminated before completion: 4.1% after drug treatment, and 0.7% after placebo. The decision to stop a driving test was 3-4 times more often made by the driving instructor than the subject. The most common reasons for stopping were the driver feeling tired or sleepy, or the driving instructor noticing signs of drowsiness and performance impairment. Although SDLP values of stopped driving tests are sometimes high, there is no clear relationship between SDLP (changes from placebo) and the decision to stop a driving test. Based on 8 studies that reported exact data, 39.6% of stopped drivers had a lower and 60.4% had a higher SDLP than 35 cm, i.e. the cut-off point of safe driving. This confirms that perception of the driver as well as judgment by the instructor of driving to be 'unsafe' differs between individuals.
Driving tests are sometimes stopped after drug treatment or placebo. The decision to stop driving is not a good correlate of objective performance.
在正常交通中的路考用于检查药物对驾驶表现的影响。尽管参与者有持照驾驶教练陪同,但根据荷兰法律,驾驶员对安全驾驶负有主要责任,并且在判断药物危及安全时不允许继续驾驶。本综述检查了停止驾驶测试的流行率和性质,以及与标准偏差的横向位置(SDLP)的关系,即“编织的汽车”。
进行了文献检索,以收集所有应用路考的临床试验出版物,检查中枢神经系统(CNS)药物的影响,如抗焦虑药、抗抑郁药、抗组胺药、镇痛药和催眠药。
47 篇论文报告了 50 项荷兰临床试验,其中 1059 名受试者参与(903 名健康志愿者和 156 名患者)。总共进行了 7232 次驾驶测试;5050 次在药物治疗后进行,2042 次在安慰剂后进行。总共有 3.1%的驾驶测试在完成前被终止:4.1%在药物治疗后,0.7%在安慰剂后。决定停止驾驶测试的是驾驶教练而不是受试者,次数是其 3-4 倍。停止驾驶测试的最常见原因是驾驶员感到疲倦或困倦,或者驾驶教练注意到困倦和表现受损的迹象。尽管停止的驾驶测试的 SDLP 值有时很高,但 SDLP(与安慰剂相比的变化)与停止驾驶测试的决定之间没有明确的关系。基于报告确切数据的 8 项研究,39.6%的停止驾驶的人 SDLP 低于 35cm,即安全驾驶的截止点,而 60.4%的人 SDLP 高于 35cm。这证实了驾驶员的感知以及教练对驾驶的“不安全”判断因人而异。
驾驶测试有时在药物治疗或安慰剂后停止。停止驾驶的决定不是客观表现的良好相关因素。